Literature DB >> 10655542

Reduced survival motor neuron (Smn) gene dose in mice leads to motor neuron degeneration: an animal model for spinal muscular atrophy type III.

S Jablonka1, B Schrank, M Kralewski, W Rossoll, M Sendtner.   

Abstract

Spinal muscular atrophy (SMA) is caused by deletion or specific mutations of the telomeric survival motor neuron ( SMN ) gene on human chromosome 5. The human SMN gene, in contrast to the Smn gene in mouse, is duplicated and the centromeric copy on chromosome 5 codes for transcripts which preferentially lead to C-terminally truncated SMN protein. Here we show that a 46% reduction of Smn protein levels in the spinal cord of Smn heterozygous mice leads to a marked loss of the cytoplasmic Smn pool and motor neuron degeneration resembling spinal muscular atrophy type 3. Smn heterozygous mice described here thus represent a model for the human disease. These mice could allow screening for SMA therapies and help in gaining further understanding of the pathophysiological events leading to motor neuron degeneration in SMA.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10655542     DOI: 10.1093/hmg/9.3.341

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  54 in total

Review 1.  Applicability of histone deacetylase inhibition for the treatment of spinal muscular atrophy.

Authors:  Sebastian Lunke; Assam El-Osta
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

2.  Coilin forms the bridge between Cajal bodies and SMN, the spinal muscular atrophy protein.

Authors:  M D Hebert; P W Szymczyk; K B Shpargel; A G Matera
Journal:  Genes Dev       Date:  2001-10-15       Impact factor: 11.361

Review 3.  Genetically engineered models relevant to neurodegenerative disorders: their value for understanding disease mechanisms and designing/testing experimental therapeutics.

Authors:  P C Wong; H Cai; D R Borchelt; D L Price
Journal:  J Mol Neurosci       Date:  2001-10       Impact factor: 3.444

4.  Muscles in a mouse model of spinal muscular atrophy show profound defects in neuromuscular development even in the absence of failure in neuromuscular transmission or loss of motor neurons.

Authors:  Young Il Lee; Michelle Mikesh; Ian Smith; Mendell Rimer; Wesley Thompson
Journal:  Dev Biol       Date:  2011-05-30       Impact factor: 3.582

5.  The zinc finger protein ZPR1 is a potential modifier of spinal muscular atrophy.

Authors:  Saif Ahmad; Yi Wang; Gouse M Shaik; Arthur H Burghes; Laxman Gangwani
Journal:  Hum Mol Genet       Date:  2012-03-14       Impact factor: 6.150

6.  Refined characterization of the expression and stability of the SMN gene products.

Authors:  Jérémie Vitte; Coralie Fassier; Francesco D Tiziano; Cécile Dalard; Sabrina Soave; Natacha Roblot; Christine Brahe; Pascale Saugier-Veber; Jean Paul Bonnefont; Judith Melki
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

7.  Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts.

Authors:  Leigh A Skordis; Matthew G Dunckley; Baigong Yue; Ian C Eperon; Francesco Muntoni
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-17       Impact factor: 11.205

Review 8.  Spinal muscular atrophy.

Authors:  Susan T Iannaccone; Stephen A Smith; Louise R Simard
Journal:  Curr Neurol Neurosci Rep       Date:  2004-01       Impact factor: 5.081

9.  Inhibition of U snRNP assembly by a virus-encoded proteinase.

Authors:  Laura L Almstead; Peter Sarnow
Journal:  Genes Dev       Date:  2007-05-01       Impact factor: 11.361

10.  Neurotransmitter release in motor nerve terminals of a mouse model of mild spinal muscular atrophy.

Authors:  Rocío Ruiz; Lucía Tabares
Journal:  J Anat       Date:  2013-03-13       Impact factor: 2.610

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.